Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Lyka Labs Limited is an Indian pharmaceutical company focused on active pharmaceutical ingredients (APIs) and generic drug formulations, primarily serving domestic and emerging markets. The company operates manufacturing facilities in India with capabilities in complex chemistry and specialty APIs. Recent 33.9% revenue growth and 421.8% net income growth suggest successful product launches or market expansion, though negative FCF and ROE indicate ongoing investment phase or working capital challenges.
Lyka generates revenue through manufacturing and selling APIs and finished dosage formulations with 60.5% gross margins, indicating strong pricing power in specialty molecules or differentiated product portfolio. The 35.9% operating margin reflects efficient manufacturing scale, though 5.7% net margin suggests high interest costs, tax burdens, or one-time charges. Competitive advantages likely include regulatory approvals (USFDA, EUGMP), established distribution networks in India, and technical expertise in complex chemistry. Pricing power derives from product differentiation, regulatory barriers to entry, and limited competition in niche therapeutic areas.
New product approvals and launches - USFDA ANDA approvals, EUGMP certifications for key molecules driving revenue visibility
API pricing dynamics - raw material costs (especially Chinese API imports) and competitive intensity in key molecules
Regulatory inspection outcomes - warning letters, import alerts, or facility clearances materially impact revenue and investor sentiment
Working capital management - inventory levels and receivables collection affecting cash generation given current negative FCF
Currency movements - INR/USD exchange rates affecting export realization and import costs for raw materials
Regulatory compliance risk - USFDA and EUGMP inspections can result in warning letters, import alerts, or facility shutdowns, materially impacting revenue. Indian pharma industry has faced heightened scrutiny over data integrity and manufacturing practices.
Pricing pressure in generic markets - increasing competition from Chinese manufacturers and aggressive procurement by government health programs (Ayushman Bharat in India, Medicaid/340B in US) compressing margins on mature molecules
API supply chain concentration - dependence on Chinese raw material suppliers for key starting materials creates vulnerability to geopolitical tensions, quality issues, or supply disruptions
Intense competition from larger Indian generic manufacturers (Sun Pharma, Dr. Reddy's, Cipla) with greater scale, broader portfolios, and stronger regulatory track records
Chinese API manufacturers expanding downstream into formulations with cost advantages and vertical integration
Limited product differentiation in commodity generic segments leading to price-based competition and margin erosion
Negative ROE of -0.6% and ROA of -0.4% indicate capital is not generating returns, suggesting either recent losses, equity dilution, or inefficient asset deployment
Negative free cash flow of -$0.1B despite positive operating margins indicates working capital build or aggressive capex potentially straining liquidity
Current ratio of 1.41x provides modest liquidity cushion but requires monitoring given cash consumption and potential working capital pressures in pharmaceutical distribution
low - Pharmaceutical demand is relatively inelastic as healthcare needs persist regardless of economic conditions. However, generic drug pricing faces pressure during economic downturns as payers and governments negotiate aggressively. Indian domestic market growth correlates moderately with GDP growth as healthcare access expands with rising incomes. Export markets to emerging economies show moderate cyclicality.
Rising interest rates moderately impact Lyka through higher financing costs on working capital and capex funding, though 0.31 D/E suggests manageable debt levels. More significantly, higher rates in developed markets strengthen USD relative to INR, improving export realization for API and formulation exports. Rate increases also pressure valuation multiples for growth-stage pharma companies, particularly given current 25.1x EV/EBITDA.
Moderate credit exposure through working capital financing needs and customer payment terms. Pharmaceutical distributors and hospital systems typically operate on 60-90 day payment cycles, requiring revolving credit facilities. Tightening credit conditions could pressure working capital and explain current negative FCF. Export customers in emerging markets carry higher credit risk during global financial stress.
growth - The 33.9% revenue growth, 421.8% net income growth, and 400% EPS growth attract growth investors despite negative FCF. However, -41.4% one-year return and -33% six-month return indicate momentum has reversed, likely attracting contrarian value investors betting on turnaround. The negative ROE and high EV/EBITDA of 25.1x suggest market is pricing in future growth rather than current profitability, typical of growth-stage pharma companies investing in capacity and product pipeline.
high - The -41.4% one-year return and -21.3% three-month return demonstrate significant volatility. Indian pharmaceutical stocks exhibit high beta due to regulatory event risk (USFDA inspections), binary product approval outcomes, and currency fluctuations. Small-cap pharma companies like Lyka with $2.4B market cap face additional liquidity-driven volatility and limited analyst coverage.
